Allergy and Immunology · Tarrytown, NY
NPI
1396727665
Since 2005
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
200 White Plains Rd Ste 201
Tarrytown, NY, 10591
Phone (914) 631-3053
Groups this clinician bills Medicare through
Medicare paid, 2024
$80K
7,644 services
Medicare patients, 2024
237
Average age 73
Drug cost, 2024
$3.2M
1,260 prescriptions
Company payments, 2025
$23K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark Davis-Lorton was code 95004 (test - miscellaneous), 5,992 times for 107 patients. In total Mark Davis-Lorton billed 7,644 services in 23 codes, and Medicare paid $80K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-05-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 5,992 | 107 | $3.81 | $23K |
| 95024 Test - Miscellaneous | Office | 487 | 33 | $7.52 | $3,661 |
| 99214 Office E&M - Established | Office | 151 | 90 | $112.62 | $17K |
| 95117 Treatment - Miscellaneous | Office | 147 | 12 | $12.20 | $1,793 |
| 99213 Office E&M - Established | Office | 113 | 88 | $79.42 | $8,975 |
| 95012 Pulmonary | Office | 76 | 45 | $18.10 | $1,376 |
| 99203 Office E&M - New | Office | 68 | 68 | $101.92 | $6,931 |
| 99204 Office E&M - New | Office | 48 | 48 | $146.93 | $7,053 |
| 95076 Test - Miscellaneous | Office | 15 | 15 | $119.39 | $1,791 |
By year: 2022 $76K for 7,773 services; 2023 $75K for 7,899 services; 2024 $80K for 7,644 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87635 COVID Specific | 15 | 12 | $50.42 | $756 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark Davis-Lorton prescribed most often to Medicare patients was Azelastine Hcl, with 249 prescriptions and refills. In total Mark Davis-Lorton wrote 1,260 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azelastine Hcl Generic | 249 | 304 | 76 | $6,625 |
| Fluticasone Propionate Generic | 169 | 227 | 69 | $2,235 |
| Levocetirizine Dihydrochloride Generic | 92 | 136 | 29 | $1,264 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 89 | 98 | 18 | $60K |
| Montelukast Sodium Generic | 64 | 104 | 14 | $668 |
| Takhzyro Lanadelumab-Flyo | 50 | 50 | Under 11 | $1.9M |
| Dupixent Pen Dupilumab | 40 | 44 | Under 11 | $170K |
| Ipratropium Bromide Generic | 34 | 53 | 14 | $1,105 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 32 | 34 | 20 | $827 |
| Breo Ellipta Fluticasone/Vilanterol | 30 | 34 | Under 11 | $14K |
| Triamcinolone Acetonide Generic | 27 | 41 | 14 | $368 |
| Symbicort Budesonide/Formoterol Fumarate | 26 | 36 | Under 11 | $8,385 |
| Amitriptyline Hcl Generic | 25 | 25 | Under 11 | $156 |
| Arnuity Ellipta Fluticasone Furoate | 25 | 25 | Under 11 | $5,481 |
| Dupixent Syringe Dupilumab | 24 | 24 | Under 11 | $87K |
Brand drugs: 398 claims; generic drugs: 862 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Davis-Lorton $23K ($23K in general payments such as food, travel and fees) from 20 companies. The largest payer was Pharming Healthcare, Inc. with $8,004.
| Company | Payments | Amount |
|---|---|---|
| Pharming Healthcare, Inc. | 13 | $8,004 |
| AstraZeneca Pharmaceuticals LP AZN | 14 | $7,387 |
| BioCryst Pharmaceuticals, Inc. BCRX | 7 | $4,424 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $1,625 |
| BioCryst US Sales Co., LLC | 9 | $498 |
| CSL Behring CSL.AX | 8 | $334 |
| Genzyme Corporation SNY | 6 | $158 |
| Ionis Pharmaceuticals, Inc. IONS | 2 | $136 |
| Optinose US, Inc. | 4 | $87.89 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $64.31 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.